Home Tags ODAC

Tag: ODAC

Advisory Committee Votes in Favor of Positive Benefit/Risk Profile for Belantamab...

ADC Review | Editorial Team
The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted 12-0 in favor of positive benefit/risk profile for belantamab mafodotin...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

MADE POSSIBLE BY
MabPlex

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.